Rocket Pharmaceuticals (RCKT) Expected to Release Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rocket Pharmaceuticals to post earnings of ($0.39) per share and revenue of $0.20 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.86 by $0.22. During the same period last year, the company earned ($0.62) earnings per share. On average, analysts expect Rocket Pharmaceuticals to post ($1.36) EPS for the current fiscal year and ($1.44) EPS for the next fiscal year.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ RCKT opened at $2.58 on Thursday. The company has a current ratio of 9.24, a quick ratio of 9.24 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals has a twelve month low of $2.16 and a twelve month high of $5.45. The business has a 50 day simple moving average of $3.01 and a 200-day simple moving average of $3.47. The company has a market capitalization of $283.23 million, a price-to-earnings ratio of -15.18 and a beta of 0.50.

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 75,364 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $3.40, for a total value of $256,237.60. Following the transaction, the general counsel directly owned 598,489 shares of the company’s stock, valued at $2,034,862.60. This represents a 11.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Christopher Stevens sold 36,658 shares of Rocket Pharmaceuticals stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $3.50, for a total transaction of $128,303.00. Following the completion of the sale, the chief operating officer directly owned 505,784 shares of the company’s stock, valued at approximately $1,770,244. The trade was a 6.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 125,977 shares of company stock worth $432,273 over the last ninety days. 21.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on RCKT. Wall Street Zen upgraded Rocket Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 17th. Leerink Partners dropped their target price on Rocket Pharmaceuticals from $7.00 to $4.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 7th. Weiss Ratings cut Rocket Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Chardan Capital reissued a “buy” rating and set a $11.00 price target on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. Finally, Needham & Company LLC raised shares of Rocket Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.77.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses lentiviral and adeno-associated virus (AAV) technologies to address genetic disorders with significant unmet medical needs, including hematologic, metabolic, and cardiovascular conditions.

Rocket’s pipeline has included RP-L102 for Fanconi anemia, a rare inherited bone-marrow-failure disorder; RP-L201 for leukocyte adhesion deficiency-I, an immune disorder; and gene therapy programs targeting Danon disease and arrhythmogenic cardiomyopathy.